High Spinal Anesthesia and the Incidence of Delirium After Cardiac Surgery

Sponsor
University of Manitoba (Other)
Overall Status
Recruiting
CT.gov ID
NCT05374356
Collaborator
(none)
50
1
2
19
2.6

Study Details

Study Description

Brief Summary

This is a feasibility study to determine if enough patients undergoing elective or urgent cardiac surgery, can be enrolled in a study where patients are randomized to receive high spinal anesthesia as an adjunct to general anesthesia for their cardiac surgery. The primary clinical outcome will be the incidence of post-operative delirium.

Condition or Disease Intervention/Treatment Phase
  • Drug: Intrathecal bupivacaine and morphine
N/A

Detailed Description

Intervention

Patients will be randomized to either general anesthesia (GA) or HSA + GA.

  1. Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).

  2. Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.

  3. Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation.

  4. Intraoperative physiological data (mean blood pressure, end-tidal anesthetic gas concentrations, BIS score) will be recorded and downloaded to a laptop computer using the Trend Face Solo acquisition system for subsequent analysis.

  5. The routine postoperative care map for the postoperative cardiac intensive care unit (ICCS) will be followed.

  6. All patients will be assessed by the study investigator for presence/absence of delirium on postoperative days 1,2 & 3, as well as routine nursing assessment by the delirium assessment tool CAM-ICU, routinely done by nursing staff. Chart reviews will be conducted to confirm any additional incidence of delirium.

  7. All patients will be contacted at one and three months after surgery and asked to complete a ten-minute survey (Postop QoR-15 questionnaire) assessing their quality of recovery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized to either general anesthesia (GA) or HSA + GA.Patients will be randomized to either general anesthesia (GA) or HSA + GA.
Masking:
Single (Outcomes Assessor)
Masking Description:
All patients will be assessed by the study investigator for presence/absence of delirium on postoperative days 1,2 & 3, as well as routine nursing assessment by the delirium assessment tool CAM-ICU, routinely done by nursing staff. Chart reviews will be conducted to confirm any additional incidence of delirium. The data collectors will not be aware whether the patient had a spinal anesthetic or not.
Primary Purpose:
Other
Official Title:
High Spinal Anesthesia and the Incidence of Delirium After Cardiac Surgery: a Randomized-controlled Feasibility Trial
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: High spinal anesthesia

Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg). Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated. Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation.

Drug: Intrathecal bupivacaine and morphine
Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
Other Names:
  • Drug: bupivacaine 0.75% in dextrose (0.3 to 0.6 mls/kg)
  • Drug: preservative free morphine 3 mcg/kg
  • No Intervention: Control group

    Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated. Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation.

    Outcome Measures

    Primary Outcome Measures

    1. Recruitment rate [One year]

      Mean number of patients recruited per week) (n)

    2. Protocol adherence measure - establishment of spinal anesthetic [Day of surgery]

      In order to assess protocol adherence (%), in patients randomized to spinal anesthesia, an 80% success rate in establishing a spinal anesthetic will be considered as protocol adherence.

    3. Protocol adherence measure - completion of delirium assessments [Day of surgery until five days post-operatively]

      In order to assess protocol adherence (%), completion of 90% of scheduled delirium assessments will be considered protocol adherence.

    Secondary Outcome Measures

    1. Early incidence of post-operative delirium [Day of surgery until five days post-operatively]

      Duration of delirium (days) as assessed by the number of positive Confusion Assessment Method (CAM) as assessed by study investigator

    2. Verification of early incidence of post-operative delirium [Day of surgery until five days post-operatively]

      Duration of delirium (days) as assessed by the number of positive CAM Scores as assessed by nursing/physicians (by chart review).

    3. Late incidence of post-operative delirium [Post-operative day 6 until post-operative day 14 or discharge from hospital whichever occurs first.]

      Duration of delirium (days) as assessed by the number of positive CAM scores as assessed by study investigator from post-operative day 6 to post-operative day 14 or discharge from hospital

    4. Verification of late incidence of post-operative delirium [Post-operative day 6 until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Duration of delirium (days) as assessed by the number of positive CAM scores as assessed by nursing/physicians (by chart review) from post-operative day 6 to discharge from hospital

    5. Use of haloperidol post-operatively [Day of surgery until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Incidence (%) and total dose of haloperidol, in milligrams, for treatment of agitation as ordered by attending medical staff from day of surgery to discharge from hospital

    6. Use of quetiapine post-operatively [Day of surgery until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Incidence (%) and total dose of quetiapine, in milligrams, for treatment of agitation as ordered by attending medical staff from day of surgery to discharge from hospital.

    7. Use of risperidone post-operatively [Day of surgery until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Incidence (%) and total dose of risperidone, in milligrams, for treatment of agitation as ordered by attending medical staff from day of surgery to discharge from hospital.

    8. Use of dexmedetomidine post-operatively [Day of surgery until post-operative day 5 or discharge from the intensive care unit whichever comes first..]

      Incidence (%) of use of dexmedetomidine infusions, for treatment of agitation as ordered by attending medical staff from day of surgery to discharge from the intensive care unit.

    Other Outcome Measures

    1. Incidence of intraoperative extubation [Day of surgery]

      Incidence of extubation in the operating room (%)

    2. Duration of ICU intubation [Day of surgery until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Duration of ICU intubation in hours for those patients brought intubated to the ICU

    3. Post-operative pain scores at rest [Post-operative day 1 until post-operative day 3]

      VAS pain scores (visual analog score) (0 is no pain, 10 is the worst pain possible) at rest for 3 days post-operatively.

    4. Post-operative pain scores with deep breathing [Post-operative day 1 until post-operative day 3]

      VAS pain scores (0 is no pain, 10 is the worst pain possible) with deep breathing for 3 days post-operatively.

    5. Post-operative hydromorphone administered [Day of surgery until post-operative day 3]

      Total hydromorphone use including intravenous and oral administration will be recorded for the first 48 hours postoperatively. Hydromorphone totals will be converted to morphine equivalents using MD Calcs algorithm (https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator).

    6. Post-operative fentanyl administered [Day of surgery until post-operative day 3]

      Total fentanyl use including intravenous and oral administration will be recorded for the first 48 hours postoperatively. Fentanyl totals will be converted to morphine equivalents using MD Calcs algorithm (https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator).

    7. Post-operative codeine administered [Day of surgery until post-operative day 3]

      Total codeine use including intravenous and oral administration will be recorded for the first 48 hours postoperatively. Codeine totals will be converted to morphine equivalents using MD Calcs algorithm (https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator).

    8. Post-operative morphine administered [Day of surgery until post-operative day 3]

      Total morphine use, in milligrams, including intravenous and oral administration will be recorded for the first 48 hours postoperatively.

    9. Intraoperative hypotension [Day of surgery]

      Length of time (mins) mean arterial blood pressure is less than 55 mmHg

    10. Intraoperative end-tidal gas concentration [Day of surgery]

      Mean intraoperative end-tidal gas concentration (%)

    11. Intraoperative depth of anesthesia [Day of surgery]

      Mean intraoperative bispectral index (BIS). The BIS scale range is from 0 to 100, with 0 representing no measurable electrical brain activity and 100 the electrical activity of an awake, conscious individual. Currently BIS scores are attempted to be kept between 20 and 40 during surgery to ensure adequate depth of anesthesia.

    12. Intraoperative sufentanil administered [Day of surgery]

      Total dose of intraoperative sufentanil in micrograms. Sufentanil dosage will be converted to morphine equivalents using the MD Calcs algorithm (https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator)

    13. Intraoperative hydromorphone administered [Day of surgery]

      Total dose of intraoperative hydromorphone in milligrams. Hydromorphone doses will be converted to morphine equivalents using the MD Calcs algorithm (https://www.mdcalc.com/morphine-milligram-equivalents-mme-calculator)

    14. Intraoperative midazolam administered [Day of surgery]

      Total dose of intraoperative midazolam in milligrams.

    15. Intraoperative ketamine administered [Day of surgery]

      Total dose of intraoperative ketamine in milligrams

    16. Intraoperative glucose level [Day of surgery]

      Highest intraoperative glucose level in millimoles per litre.

    17. Intraoperative insulin administered [Day of surgery]

      Total intraoperative insulin administered in units of insulin.

    18. Total RBC utilization [Day of surgery until post-operative day 3]

      Total RBC administered (units) both intraoperatively, and postoperatively until post-operative day 3..

    19. Total platelet utilization [Day of surgery until post-operative day 3]

      Total units of platelets administered (adult doses of platelets ) both intraoperatively, and postoperatively until post-operative day 3

    20. Return to OR for bleeding [Day of surgery until post-operative day 3]

      Incidence of a return to the operating room for bleeding (%)

    21. Vasopressor (norepinephrine or phenylephrine or vasopressin) use at 12 hours [First 12 hours postoperatively]

      Incidence of use of either norepinephrine, phenylephrine or vasopressin at 12 hours postoperatively (%)

    22. Vasopressor (norepinephrine, phenylephrine or vasopressin) use at 24 hours [12 to 24 hours postoperatively]

      Incidence of use of norepinephrine, phenylephrine or vasopressin administered at 24 hours postoperatively (%)

    23. Vasopressor (norepinephrine, phenylephrine or vasopressin) use at >24 hours [Post-operative day 2 to post-operative day 7]

      Incidence of norepinephrine, phenylephrine or vasopressin use longer than 24 hours postoperatively (%)

    24. Incidence of re-intubation [Day of surgery until 14 days post-operatively or discharge from hospital, whichever occurs first.]

      Incidence of re-intubation postoperatively (%) from day of surgery to discharge from hospital

    25. ICU re-admission [Post-operative day 2 until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Incidence of re-admission to ICU for any reason from post-operative day 2 to post-operative day 14 or discharge from hospital (%)

    26. Hospital length of stay [Time (days) in hospital from post-operative 1 to 30 (or through discharge from hospital)]

      Postoperative hospital length of stay in days

    27. ICU length of stay [Time (days) in ICU from post-operative day 1 to 5 (or through discharge from hospital)]

      Postoperative ICU length of stay in days

    28. Major medical complications [Day of surgery until post-operative day 14 or discharge from hospital, whichever occurs first.]

      Incidence of major medical complications (%) defined as one or more of: a. Atrial fibrillation b. Pneumonia c. Acute kidney injury (defined as a doubling of pre-operative creatinine) d. Need for dialysis e. Wound infection f. Stroke g. Other

    29. Post-operative quality of recovery - one month [30 days post surgery]

      Postoperative quality of life score (Postop QoR-15) will be used to assess quality of recovery at one month postoperatively. The Post QoR-15 scale ranges from 0 to 150, with 0 representing the poorest quality of recovery and 150 the best quality of recovery.

    30. Post-operative quality of recovery - three months [90 days post surgery]

      Postoperative quality of life score (Postop QoR-15) will be used to assess quality of recovery at three month postoperatively. The Post QoR-15 scale ranges from 0 to 150, with 0 representing the poorest quality of recovery and 150 the best quality of recovery.

    31. Post-operative creatinine level [Day of surgery until 14 days post-operatively or hospital discharge, whichever occurs first.]

      Highest post-operative creatinine (umol/l) level recorded during hospital stay.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult (>18 years old) patients

    • Undergoing elective or urgent cardiac surgical procedures with cardiopulmonary bypass

    Exclusion Criteria:
    • Contraindications to spinal anesthesia such as active anticoagulation, clopidogrel within 7 days of surgery, ticagrelor within 3 days of surgery and all other contraindications to lumbar puncture

    • Pre-existing psychiatric diagnoses such as schizophrenia or manic-depressive disorder

    • Complex aortic surgery (> hemi-arch repair, descending thoracic surgery)

    • Difficult airway requiring an awake intubation

    • BMI > 50

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St. Boniface Hospital Winnipeg Manitoba Canada R2H 2A6

    Sponsors and Collaborators

    • University of Manitoba

    Investigators

    • Study Director: Doug Maguire, MD, University of Manitoba

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Manitoba
    ClinicalTrials.gov Identifier:
    NCT05374356
    Other Study ID Numbers:
    • HS23755 B2020:026
    First Posted:
    May 16, 2022
    Last Update Posted:
    May 16, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Manitoba
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 16, 2022